Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells

The Prostate
Z WuD Theodorescu

Abstract

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is lost as a function of prostate tumor androgen dependence. While the transcriptional activity of the androgen receptor (AR) is inhibited by PTEN in androgen sensitive prostate cancer (CaP), the role of PTEN in androgen disease is unclear. We developed a system where PTEN can be conditionally re-expressed at physiologic levels into a PTEN null metastatic human CaP cell line, C4-2, and androgen responsiveness examined. PTEN induction reduces cell growth and blocks the growth effect of synthetic androgen R1881. The anti-androgen Casodex enhances the growth-inhibitory action of PTEN and this effect is independent of Akt phosphorylation. Combined PTEN induction and Casodex, result in a further decrease in prostate specific antigen promoter activity compared to PTEN but not Casodex alone. PTEN induction confers androgen independent CaP cells enhanced responsiveness to the anti-proliferative effects of anti-androgens and this action may involve non-AR mediated effects.

References

May 1, 1994·International Journal of Cancer. Journal International Du Cancer·H C WuL W Chung
Feb 1, 1993·Current Opinion in Genetics & Development·M E Perry, A J Levine
Nov 14, 1997·Proceedings of the National Academy of Sciences of the United States of America·F B FurnariW K Cavenee
Jun 6, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y E WhangC L Sawyers
Nov 13, 1998·Proceedings of the National Academy of Sciences of the United States of America·M P MyersN K Tonks
Nov 13, 1998·Science·M H CardoneJ C Reed
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·S RamaswamyW R Sellers
May 4, 1999·Trends in Cell Biology·T Maehama, J E Dixon
Jun 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·H K LinC Chang
Mar 20, 2002·Nature Reviews. Cancer·B J Feldman, D Feldman
May 9, 2002·Molecular and Cellular Biology·Bangyan StilesHong Wu
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven P BalkGlenn J Bubley
Mar 28, 2003·Lancet·Ashesh B Jani, Samuel Hellman
Jun 20, 2003·Cell Death and Differentiation·E C Y LeeM Tenniswood
Aug 14, 2003·Journal of Molecular Endocrinology·B NanM Marcelli
Jan 2, 2004·Nature Medicine·Charlie D ChenCharles L Sawyers
Apr 6, 2004·Molecular and Cellular Endocrinology·Helmut DotzlawAria Baniahmad
Mar 25, 2005·Endocrine-related Cancer·Paramita M GhoshJeffrey I Kreisberg

❮ Previous
Next ❯

Citations

Apr 28, 2011·Nature Reviews. Clinical Oncology·Alexander N ShoushtariCarrie W Rinker-Schaeffer
Feb 14, 2007·Prostate Cancer and Prostatic Diseases·E RichterA Dobi
Sep 17, 2010·Genes & Development·Michael M Shen, Cory Abate-Shen
Feb 18, 2009·BJU International·Christopher C UzohRaj A Persad
Sep 17, 2016·Oncotarget·Hannah NipShahana Majid
Oct 17, 2020·NPJ Breast Cancer·Anna R MichmerhuizenCorey W Speers
Apr 20, 2021·Journal of the Endocrine Society·Olga AstapovaStephen R Hammes

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.